Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris 16:39:34 26/06/2024 BST After market 20:55:35
90.79 EUR -0.09% Intraday chart for Sanofi 90.41 -0.42%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Sanofi-backed Drug Developer Formation Bio Raises $372 Million MT
Sanofi-backed Formation Bio raises $372 million in late-stage funding round RE
Euroapi: updated outlook for 2024 CF
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
Sanofi Starts Bidding Process to Sell Consumer Health Division, Bloomberg Reports DJ
Sanofi Invites Initial Bids for $20 Billion Consumer Spinoff MT
TrialSpark, Inc. announced that it has received $372 million in funding from a group of investors CI
Sector Update: Health Care Stocks Ease Late Afternoon MT
Sanofi Progresses on Consumer Health Separation; Sale, Spinoff Still on Table MT
US CDC alerts healthcare providers of increase in dengue cases RE
Sector Update: Health Care Stocks Easing Tuesday Afternoon MT
Sanofi Seeks Initial Bids for Consumer Health Division MT
Sanofi Seeks Initial Bids for Consumer Health Division, Bloomberg Says MT
SANOFI : UBS remains its Buy rating ZD
EvolutionaryScale lands $142 mln to advance AI in biology RE
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading MT
SANOFI : JP Morgan sticks Neutral ZD
CAC40: starts the week on the right foot, approaches 7700pts CF
Sanofi: new Director of Group Corporate Affairs CF
Sanofi Appoints Audrey Duval Derveloy as Executive Vice President, Global Head of Corporate Affairs and Member of its Executive Committee, Effective July 1, 2024 CI
Sanofi: new positive data in hemophilia CF
US FDA Accepts Sanofi's New Drug Application for Hemophilia Treatment Fitusiran MT
Sanofi to Present New Data from its Hemophilia Portfolio at the 32nd Congress of the International Society on Thrombosis and Haemostasis CI
Cybersecurity firm Semperis raises $125 mln from JP Morgan, Hercules Capital RE
France’s Sanofi Partners with South Africa’s Biovac for Polio Vaccine Initiative MT
Chart Sanofi
More charts
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
90.87 EUR
Average target price
108.2 EUR
Spread / Average Target
+19.06%
Consensus
  1. Stock Market
  2. Equities
  3. SAN Stock
  4. News Sanofi
  5. Sanofi Informs Denali That Potential ALS Drug Misses Primary Endpoint of Phase 2 Study